Neuropathy Outcome Assessment

Uses

Risks & contraindications

Highlighted claims

• The primary outcome is the incidence of CTCAE grade 2 or higher chemotherapy-induced peripheral neuropathy of the hand, defined as onset in the fingers regardless of whether one or both hands are affected. — Possible preventive effect of surgical glove compression therapy on oxaliplatin-induced peripheral neuropathy: study protocol of a multicentre, phase II/III, randomised controlled trial–the Hiroshima Surgical Study Group of Clinical Oncology (HiSCO)-12 trial
• FACT/GOG-Ntx-12 and EORTC QLQ-CIPN20 are patient-reported outcome measures selected to capture patients' subjective neuropathy experience and its effect on quality of life, complementing clinician-assessed CTCAE grading. — Possible preventive effect of surgical glove compression therapy on oxaliplatin-induced peripheral neuropathy: study protocol of a multicentre, phase II/III, randomised controlled trial–the Hiroshima Surgical Study Group of Clinical Oncology (HiSCO)-12 trial
• Safety monitoring for glove compression includes adverse events such as blood flow impairment, pain, and allergic skin reactions during or after glove application. — Possible preventive effect of surgical glove compression therapy on oxaliplatin-induced peripheral neuropathy: study protocol of a multicentre, phase II/III, randomised controlled trial–the Hiroshima Surgical Study Group of Clinical Oncology (HiSCO)-12 trial
• The Debiopharm Neurologic and Sensory Toxicity Criteria (DEB-NTC) will evaluate persistence of OIPN symptoms and categorises severity by whether symptoms last less than or more than 7 days. — Possible preventive effect of surgical glove compression therapy on oxaliplatin-induced peripheral neuropathy: study protocol of a multicentre, phase II/III, randomised controlled trial–the Hiroshima Surgical Study Group of Clinical Oncology (HiSCO)-12 trial